Clinical trial
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
NCT00447122 · Brown University, Other · Terminated
Key facts
| NCT number | NCT00447122 |
|---|---|
| Title | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer |
| Official title | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer: A Phase I Study #108181 |
| Lead sponsor | Brown University, Other |
| Collaborators | Rhode Island Hospital The Miriam Hospital Memorial Hospital of Rhode Island |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine 1000mg/m2 30 minutes, Lapatinib 1000mg/d, Lapatinib 1500mg/d, Gemcitabine 1000mg/m2 100minutes, Oxaliplatin 100mg/m2 |
| Enrollment | 25 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Mar 14, 2007 |
| Last update posted | Mar 8, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: